Pharma giants have been quick to tout their efforts to help the Trump administration rein in runaway drug prices.
Mylan's Beat Lifts Hopes That Worst Is Over for Generic Makers
Investors have mostly been willing to hold their nose over Hospira as Pfizer’s stock surged this year.
Pfizer Narrows Forecast as Its Older Drugs Business Struggles
Merck and Bristol-Myers Cancer Race Could Turn Into Deals Derby
Merck Plans $10 Billion Buyback as Cancer Drug Tops Views
Drug Lobby Sets Stage for Free-Speech Battle Over Prices in Ads
Pfizer Veteran Bourla to Take Over CEO Role From Ian Read
Trump Eyeing ‘Disruptive’ Changes to Drug Pricing, Health Secretary Says
Pfizer to Idle Plants in North Carolina With Hurricane Florence Approaching
Generic Drugmakers Struggle Despite U.S. Push for Copycats
Mylan Plans Strategic Review as North American Sales Plummet
U.S Federal Trade Commission indicated it wants Germany’s Linde AG, Praxair Inc. to sell more assets before approving deal.
The advantages of pharmaceutical research on the International Space Station.
Trump’s use of the bully pulpit is likely to have little impact on drug prices in the long term.
The California law is a way of publicly pressuring pharmaceutical companies to keep prices down.
Trump says Pfizer should be “ashamed” for raising the prices of its pharmaceutical products.
Alzheimer's Research Gets Glimmer of Hope, Not for First Time
Not quite a female Viagra - it’s a pill to restore a woman’s appetite for sex.
Drugmaker Revives Female Libido Pill Addyi, at Half the Price
U.S. Names Drugmakers ‘Gaming’ Safety System to Shield Profits